Journal article

Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors

Chloe Pek Sang Tang, Julie McMullen, Constantine Tam

Leukemia & Lymphoma | TAYLOR & FRANCIS LTD | Published : 2018

DOI: 10.1080/10428194.2017.1375110

Citation metrics

10Web of Science
7Scopus

Keywords

Ibrutinib
Therapeutic Target
Chronic Lymphocytic-Leukemia
Humans
Anticoagulants
Atrial-Fibrillation
Hematology
Protein Kinase Inhibitors
Cardiotoxicity
Agammaglobulinaemia Tyrosine Kinase
Pyrazoles
B-Cell Receptor
Atrial Fibrillation
Term-Follow-Up
Rhythm Control
Treatment Outcome
Science & Technology
Oncology
Clinical Trials As Topic
Open-Label
Waldenstroms Macroglobulinemia
Acalabrutinib Acp-196
Single-Agent Ibrutinib
Pyrimidines
Signal Transduction
Antineoplastic Agents
Leukemia, Lymphocytic, Chronic, B-Cell
Life Sciences & Biomedicine
Bruton Kinase Inhibitor